{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:43:19Z","timestamp":1787755399239,"version":"build-2784847793"},"reference-count":33,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Huai\u2019an First People\u2019s Hospital innovation team project","award":["YCT202304"],"award-info":[{"award-number":["YCT202304"]}]},{"name":"Xuzhou Medical University science and technology development fund surface project","award":["XYFM202311"],"award-info":[{"award-number":["XYFM202311"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Geriatr Psychiatry Neurol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The study aimed to evaluate the impact of Botulinum toxin A (BoNT\/A) on neuropsychiatric symptoms in Parkinson\u2019s disease (PD) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 125 PD patients and an equal number of age- and gender-matched healthy controls were involved. Mental health status was assessed using the Cornell Medical Index (CMI) self-assessment questionnaire. Sixty-four PD patients exhibiting neuropsychiatric symptoms were selected for the controlled study and randomly grouped into treatment and control groups. The treatment group received BoNT\/A injections, while the control group received a placebo. The primary outcome measures included depression scores from the CMI and the proportion of patients displaying improvement in neuropsychiatric symptoms at 8\u00a0weeks post-treatment. The secondary outcome was other CMI scores at 4, 8, and 12\u00a0weeks post-treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The outcomes revealed that PD patients had significantly higher scores in various neuropsychiatric factors compared to healthy controls. At 4\u00a0weeks post-treatment, the treatment group displayed improvements in depression and tension. At 8 weeks post-treatment, they exhibited significant reductions in depression, anxiety, sensitivity, and tension compared to the control group. Moreover, a notably higher percentage of patients in the treatment group showed improvement in neuropsychiatric symptoms compared to the control group. At 12\u00a0weeks post-treatment, the treatment group exhibited significant improvements in somatization, depression, sensitivity, and tension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PD patients commonly experience multiple neuropsychiatric symptoms, and BoNT\/A has demonstrated efficacy in alleviating these symptoms. Specifically, BoNT\/A was found to effectively alleviate somatization, tension, anxiety, depression, and sensitivity in PD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08919887241281066","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T10:56:34Z","timestamp":1725447394000},"page":"223-231","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Neuropsychiatric Symptoms in Parkinson\u2019s Disease With Botulinum Toxin A: A 12 week Randomized, Double-Blind, Placebo-Controlled Trial"],"prefix":"10.1177","volume":"38","author":[{"given":"Xiaofeng","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Neurology, Huai\u2019an First People\u2019s Hospital, The Affiliated Huai\u2019an No.1 People\u2019s Hospital of Nanjing Medical University, Huaian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huai\u2019an First People\u2019s Hospital, The Affiliated Huai\u2019an No.1 People\u2019s Hospital of Nanjing Medical University, Huaian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huai\u2019an First People\u2019s Hospital, The Affiliated Huai\u2019an No.1 People\u2019s Hospital of Nanjing Medical University, Huaian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huai\u2019an First People\u2019s Hospital, The Affiliated Huai\u2019an No.1 People\u2019s Hospital of Nanjing Medical University, Huaian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huai\u2019an First People\u2019s Hospital, The Affiliated Huai\u2019an No.1 People\u2019s Hospital of Nanjing Medical University, Huaian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0070-1870","authenticated-orcid":false,"given":"Qiu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huai\u2019an First People\u2019s Hospital, The Affiliated Huai\u2019an No.1 People\u2019s Hospital of Nanjing Medical University, Huaian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"issue":"1","key":"e_1_3_4_2_2","first-page":"70","article-title":"The progress on the use of botulinum toxin type A therapy in Parkinson\u2032s disease","volume":"55","author":"Bai R","year":"2022","unstructured":"Bai R, Tang Y, Lazhen S, Wang C. The progress on the use of botulinum toxin type A therapy in Parkinson\u2032s disease. Chin J Neurol. 2022;55(1):70-76.","journal-title":"Chin J Neurol"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00330-6"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.200"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00218-X"},{"issue":"9","key":"e_1_3_4_6_2","first-page":"745","article-title":"Clinical study on the efficacy and safety of botulinum toxin A in the treatment of Parkinson\u2032s disease with depression","volume":"52","author":"Lyu A","year":"2019","unstructured":"Lyu A, Fan Y, Tang L, et al. Clinical study on the efficacy and safety of botulinum toxin A in the treatment of Parkinson\u2032s disease with depression. Chin J Neurol. 2019;52(9):745-751.","journal-title":"Chin J Neurol"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2012.01.027"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2013.11.006"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08845"},{"issue":"7","key":"e_1_3_4_10_2","first-page":"982","article-title":"Efficacy of Botox versus placebo for treatment of patients with major depression","volume":"46","author":"Zamanian A","year":"2017","unstructured":"Zamanian A, Ghanbari Jolfaei A, Mehran G, Azizian Z. Efficacy of Botox versus placebo for treatment of patients with major depression. Iran J Public Health. 2017;46(7):982-984.","journal-title":"Iran J Public Health"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000290"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2016.1196687"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.08.097"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2018.11.041"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins15050336"},{"issue":"4","key":"e_1_3_4_16_2","first-page":"2717","article-title":"Effects of botulinum toxin type a on mood and cognitive function in patients with Parkinson's disease and depression","volume":"13","author":"Zhu C","year":"2021","unstructured":"Zhu C, Wang K, Yu T, Liu H. Effects of botulinum toxin type a on mood and cognitive function in patients with Parkinson's disease and depression. Am J Transl Res. 2021;13(4):2717-2723.","journal-title":"Am J Transl Res"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S181820"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02801-w"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-319290"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.3869"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000801"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.166"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-021-01601-9"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000324635.49971.3d"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27438"},{"key":"e_1_3_4_27_2","volume-title":"The Face of Emotion: How Botox Affects Our Moods and Relationships","author":"Finzi E","year":"2013","unstructured":"Finzi E. The Face of Emotion: How Botox Affects Our Moods and Relationships. New York, NY: St. Martin\u2019s Press; 2013."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/2045-5380-4-11"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00909-5"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2016.06.009"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/164_2019_272"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/02699939208409689"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhn104"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33119-1"}],"container-title":["Journal of Geriatric Psychiatry and Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08919887241281066","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08919887241281066","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08919887241281066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:16:58Z","timestamp":1777501018000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08919887241281066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/08919887241281066"],"URL":"https:\/\/doi.org\/10.1177\/08919887241281066","relation":{},"ISSN":["0891-9887","1552-5708"],"issn-type":[{"value":"0891-9887","type":"print"},{"value":"1552-5708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]}}}